209 related articles for article (PubMed ID: 22064364)
1. Small molecule inhibitors of mammalian thioredoxin reductase.
Cai W; Zhang L; Song Y; Wang B; Zhang B; Cui X; Hu G; Liu Y; Wu J; Fang J
Free Radic Biol Med; 2012 Jan; 52(2):257-65. PubMed ID: 22064364
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update.
Zhang J; Zhang B; Li X; Han X; Liu R; Fang J
Med Res Rev; 2019 Jan; 39(1):5-39. PubMed ID: 29727025
[TBL] [Abstract][Full Text] [Related]
3. Thioredoxin reductase inhibitors: a patent review.
Zhang B; Zhang J; Peng S; Liu R; Li X; Hou Y; Han X; Fang J
Expert Opin Ther Pat; 2017 May; 27(5):547-556. PubMed ID: 27977313
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Thioredoxin System for Cancer Therapy.
Zhang J; Li X; Han X; Liu R; Fang J
Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
[TBL] [Abstract][Full Text] [Related]
5. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity.
Chew EH; Lu J; Bradshaw TD; Holmgren A
FASEB J; 2008 Jun; 22(6):2072-83. PubMed ID: 18180330
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
Lu J; Papp LV; Fang J; Rodriguez-Nieto S; Zhivotovsky B; Holmgren A
Cancer Res; 2006 Apr; 66(8):4410-8. PubMed ID: 16618767
[TBL] [Abstract][Full Text] [Related]
7. Natural product based inhibitors of the thioredoxin-thioredoxin reductase system.
Wipf P; Lynch SM; Birmingham A; Tamayo G; Jiménez A; Campos N; Powis G
Org Biomol Chem; 2004 Jun; 2(11):1651-8. PubMed ID: 15162219
[TBL] [Abstract][Full Text] [Related]
8. On the potential of thioredoxin reductase inhibitors for cancer therapy.
Urig S; Becker K
Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro inhibition of mice thioredoxin reductase by methylmercury.
Wagner C; Sudati JH; Nogueira CW; Rocha JB
Biometals; 2010 Dec; 23(6):1171-7. PubMed ID: 20717703
[TBL] [Abstract][Full Text] [Related]
10. A diterpenoid derivate compound targets selenocysteine of thioredoxin reductases and induces Bax/Bak-independent apoptosis.
Liu J; Mu C; Yue W; Li J; Ma B; Zhao L; Liu L; Chen Q; Yan C; Liu H; Hao X; Zhu Y
Free Radic Biol Med; 2013 Oct; 63():485-94. PubMed ID: 23732520
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy.
He J; Li D; Xiong K; Ge Y; Jin H; Zhang G; Hong M; Tian Y; Yin J; Zeng H
Bioorg Med Chem; 2012 Jun; 20(12):3816-27. PubMed ID: 22579620
[TBL] [Abstract][Full Text] [Related]
12. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
Tonissen KF; Di Trapani G
Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity.
Liu Z; Huang SL; Li MM; Huang ZS; Lee KS; Gu LQ
Chem Biol Interact; 2009 Jan; 177(1):48-57. PubMed ID: 18822278
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
Liu Y; Li Y; Yu S; Zhao G
Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
[TBL] [Abstract][Full Text] [Related]
16. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
[TBL] [Abstract][Full Text] [Related]
17. Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase.
Zhang J; Yao J; Peng S; Li X; Fang J
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):129-138. PubMed ID: 27777067
[TBL] [Abstract][Full Text] [Related]
18. Thioredoxin reductase as a pharmacological target.
Bjørklund G; Zou L; Wang J; Chasapis CT; Peana M
Pharmacol Res; 2021 Dec; 174():105854. PubMed ID: 34455077
[TBL] [Abstract][Full Text] [Related]
19. Thioredoxin reductase.
Mustacich D; Powis G
Biochem J; 2000 Feb; 346 Pt 1(Pt 1):1-8. PubMed ID: 10657232
[TBL] [Abstract][Full Text] [Related]
20. Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents.
Gandin V; Fernandes AP
Molecules; 2015 Jul; 20(7):12732-56. PubMed ID: 26184149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]